Advances in Antibody-Drug Conjugates (ADCs) Development & Preclinical Model

Advances in ADC Development and Preclinical ModelsПодробнее

Advances in Antibody-Drug Conjugates (ADCs) Development & Preclinical ModelПодробнее

Antibody-drug conjugates(ADCs) current progress and selection of preclinical animal modelsПодробнее

Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology ConferenceПодробнее

Antibody Drug Development Summit, Autumn 2021 - Greg Christianson introductionПодробнее

Challenges and Advances in Antibody-Drug Conjugates.Подробнее

JK06, a biparatopic ADC in preclinical developmentПодробнее

What are Antibody Drug Conjugates (ADCs)?Подробнее

Antibody-drug Conjugates - Where are we Going?Подробнее

Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody–drug conjugatesПодробнее

In-depth characterization of lysine-conjugated antibody-drug conjugates (ADCs) by multiplexed MS/MSПодробнее

Exploring antibody-drug conjugates (ADCs) in lung cancerПодробнее

[Webinar] Latest Technology Advances in Antibody Drug DiscoveryПодробнее

Antibody-drug Conjugates in the Clinic:Подробнее

PBPK Modeling of Antibody-Drug Conjugates – Concept and ApplicationПодробнее

Antibody-Drug Conjugate (ADC) Development - What are Antibody-drug Conjugates (ADCs)?Подробнее

Dr. Hong's Biotechnology: Antibody Drug ConjugateПодробнее

How Do Antibody-drug conjugates ADCs Work?Подробнее

The Development of a Next Generation Antibody Drug Conjugate ADCПодробнее

What are Antibody-drug Conjugates (ADCs)?Подробнее